WEBVTT - Joaquin Duato

0:00:02.920 --> 0:00:05.540
<v Speaker 1>By revenue, the biggest healthcare company in the world is

0:00:05.600 --> 0:00:09.610
<v Speaker 1>Johnson &amp; Johnson. But Johnson &amp; Johnson no longer sells Band-Aids.

0:00:10.090 --> 0:00:13.770
<v Speaker 1>It sold off its consumer product division. Now it focuses

0:00:13.870 --> 0:00:17.950
<v Speaker 1>on pharmaceuticals and medical devices. The man responsible for that

0:00:18.050 --> 0:00:21.730
<v Speaker 1>transformation of Johnson &amp; Johnson is Joaquin de Watteau. I

0:00:21.750 --> 0:00:23.790
<v Speaker 1>had a chance recently to sit down with him to

0:00:23.870 --> 0:00:25.760
<v Speaker 1>ask him why he made this transformation.

0:00:26.480 --> 0:00:29.760
<v Speaker 2>When I was preparing for this, I did some research

0:00:29.820 --> 0:00:33.150
<v Speaker 2>and I was disappointed to learn that the Band-Aids I've

0:00:33.170 --> 0:00:35.310
<v Speaker 2>been using all these years are no longer owned by

0:00:35.370 --> 0:00:38.680
<v Speaker 2>Johnson &amp; Johnson. What happened to the Band-Aids? I mean,

0:00:38.720 --> 0:00:40.500
<v Speaker 2>I thought Band-Aids were Johnson &amp; Johnson.

0:00:41.580 --> 0:00:42.760
<v Speaker 3>So it's not only you.

0:00:42.880 --> 0:00:45.190
<v Speaker 4>I think many red IDs of the company are sending

0:00:45.229 --> 0:00:49.350
<v Speaker 4>me mail regarding that same feeling. And many of them

0:00:49.409 --> 0:00:54.950
<v Speaker 4>work in our consumer sector. Even today, when I tell

0:00:54.990 --> 0:00:57.160
<v Speaker 4>people I'm the CEO of Johnson &amp; Johnson, they tell

0:00:57.180 --> 0:00:59.280
<v Speaker 4>me the baby shampoo company.

0:00:59.820 --> 0:01:01.080
<v Speaker 3>All the time, all the time.

0:01:01.380 --> 0:01:03.540
<v Speaker 2>You became the CEO, and then within a year or

0:01:03.580 --> 0:01:06.720
<v Speaker 2>two of that, you spun out your entire consumer division,

0:01:06.740 --> 0:01:08.679
<v Speaker 2>all the kind of products that I'm the one that

0:01:08.800 --> 0:01:10.860
<v Speaker 2>I buy those things at the drugstore. And all those

0:01:10.900 --> 0:01:12.580
<v Speaker 2>things you got rid of. Why did you do that?

0:01:13.280 --> 0:01:16.520
<v Speaker 3>We wanted to be more focused on medical innovation.

0:01:17.340 --> 0:01:21.770
<v Speaker 4>And the consumer business has departed from medical innovation. We

0:01:21.780 --> 0:01:26.590
<v Speaker 4>were more on areas more connected with cosmetics or over-the-counter medication,

0:01:27.130 --> 0:01:30.190
<v Speaker 4>and it didn't fit in the overall umbrella on trying

0:01:30.310 --> 0:01:37.370
<v Speaker 4>to bring medical innovation to treat tough, difficult conditions like oncology, cardiovascular,

0:01:37.670 --> 0:01:38.330
<v Speaker 4>or dementia.

0:01:38.470 --> 0:01:42.660
<v Speaker 2>You're in pharmaceuticals, and you're in medical devices. Let's talk

0:01:42.680 --> 0:01:45.480
<v Speaker 2>about pharmaceuticals. What is your biggest pharmaceutical product?

0:01:46.290 --> 0:01:49.250
<v Speaker 4>Our biggest pharmaceutical product is a drug for multiple myeloma

0:01:49.470 --> 0:01:54.150
<v Speaker 4>called Darzalex. Multiple myeloma is a blood cancer that has

0:01:54.410 --> 0:01:55.970
<v Speaker 4>improved significantly in.

0:01:56.010 --> 0:01:56.690
<v Speaker 3>The last decade.

0:01:57.280 --> 0:02:00.000
<v Speaker 4>The life expectancy of a multiple myeloma patient was about

0:02:01.000 --> 0:02:04.720
<v Speaker 4>single years. Now a multiple myeloma patient can expect to

0:02:04.780 --> 0:02:07.400
<v Speaker 4>live more than 10 years. And in some ways, we're

0:02:07.440 --> 0:02:09.820
<v Speaker 4>turning multiple myeloma into a chronic disease.

0:02:10.270 --> 0:02:14.090
<v Speaker 2>Medical devices is another thing. Pharmaceutical is one thing, medical devices.

0:02:14.150 --> 0:02:17.090
<v Speaker 2>What is your most important medical device that you have?

0:02:18.330 --> 0:02:20.130
<v Speaker 4>Look, let me tell you why we have medical devices

0:02:20.150 --> 0:02:22.740
<v Speaker 4>and pharmaceuticals. It's because I think it gives us a

0:02:22.880 --> 0:02:27.400
<v Speaker 4>long-term competitive advantage because we can span the entire patient journey.

0:02:27.760 --> 0:02:29.560
<v Speaker 3>Let's say cancer. Let's take lung cancer.

0:02:29.600 --> 0:02:33.930
<v Speaker 4>We have systems to do bronchoscopy and do diagnosis there,

0:02:33.990 --> 0:02:35.490
<v Speaker 4>robotic-assisted bronchoscopy.

0:02:35.750 --> 0:02:37.609
<v Speaker 3>We have medicines to treat lung cancer.

0:02:38.310 --> 0:02:41.510
<v Speaker 4>We also have the instruments that are used for the

0:02:41.570 --> 0:02:42.910
<v Speaker 4>surgery in lung cancer.

0:02:43.310 --> 0:02:44.550
<v Speaker 3>And we are working on.

0:02:44.550 --> 0:02:49.080
<v Speaker 4>A radiotherapy enhancer, and radiotherapy is an important therapeutic modality

0:02:49.139 --> 0:02:51.220
<v Speaker 4>for local control in lung cancer. So we can expand

0:02:51.600 --> 0:02:54.080
<v Speaker 4>the entire patient journey. What I'm more excited about medical

0:02:54.120 --> 0:02:57.260
<v Speaker 4>devices right now is that we can use technology to

0:02:57.320 --> 0:03:00.920
<v Speaker 4>make our medical devices smarter. And the most important product

0:03:00.960 --> 0:03:03.360
<v Speaker 4>that we are about to get approval from.

0:03:03.260 --> 0:03:05.790
<v Speaker 3>The FDA is a robotic surgical system.

0:03:06.310 --> 0:03:08.589
<v Speaker 4>So most of the surgery is going to have a

0:03:08.650 --> 0:03:11.800
<v Speaker 4>robotic component that's going to help improve the level of

0:03:11.880 --> 0:03:13.680
<v Speaker 4>surgery and have better outcomes.

0:03:13.700 --> 0:03:16.500
<v Speaker 2>How many different products do you have in the pharmaceutical

0:03:16.520 --> 0:03:18.399
<v Speaker 2>and how many do you have in the devices?

0:03:18.520 --> 0:03:20.310
<v Speaker 3>We have dozens of products on both sides.

0:03:20.530 --> 0:03:22.070
<v Speaker 2>So how do you keep up with all of them?

0:03:22.110 --> 0:03:24.090
<v Speaker 2>And when somebody comes along and says we have a

0:03:24.090 --> 0:03:26.870
<v Speaker 2>new product, do you actually... test the product yourself? Or

0:03:27.150 --> 0:03:28.460
<v Speaker 2>how do you decide whether you're going to go ahead

0:03:28.470 --> 0:03:30.060
<v Speaker 2>and use this product or not?

0:03:30.160 --> 0:03:32.980
<v Speaker 4>We have a large, we have a $ 15 billion regional

0:03:33.000 --> 0:03:36.400
<v Speaker 4>development budget and thousands of scientists working at Johnson &amp; Johnson.

0:03:36.930 --> 0:03:40.030
<v Speaker 4>I don't make those decisions. I trust the scientists working

0:03:40.070 --> 0:03:43.330
<v Speaker 4>at Johnson &amp; Johnson to help me in identifying and

0:03:43.350 --> 0:03:45.830
<v Speaker 4>making the decision of what's gonna have a bigger impact

0:03:45.850 --> 0:03:49.120
<v Speaker 4>on patients. And our standard is, what is going to

0:03:49.160 --> 0:03:51.280
<v Speaker 4>have a bigger impact on patients? What is going to

0:03:51.360 --> 0:03:54.160
<v Speaker 4>clearly improve the standard of care of that particular disease?

0:03:54.200 --> 0:03:55.940
<v Speaker 4>That's what we try to do every day.

0:03:56.080 --> 0:03:58.620
<v Speaker 2>Now you have the highest revenue of any healthcare company

0:03:58.660 --> 0:04:01.400
<v Speaker 2>in the world, but there's one healthcare company that has

0:04:01.420 --> 0:04:04.930
<v Speaker 2>a higher market capitalization than you, which is Eli Lilly,

0:04:05.430 --> 0:04:07.730
<v Speaker 2>and that's about roughly a trillion dollars because they have

0:04:07.750 --> 0:04:11.030
<v Speaker 2>a GLP-1 drug. How come you don't have a GLP-1 drug?

0:04:12.060 --> 0:04:13.500
<v Speaker 3>We were focused on a different area.

0:04:13.520 --> 0:04:15.940
<v Speaker 4>We were not focused on obesity or on diabetes like

0:04:16.300 --> 0:04:18.380
<v Speaker 4>Eli Lilly was. And great for them that they were

0:04:18.520 --> 0:04:22.250
<v Speaker 4>able to identify these transformational medicine GLP-1s. There's going to

0:04:22.270 --> 0:04:25.750
<v Speaker 4>be more GLP-1s coming through the pipe. Multiple companies have GLP-1s.

0:04:26.640 --> 0:04:29.500
<v Speaker 4>We have other things to pay attention to, like trying

0:04:29.540 --> 0:04:32.600
<v Speaker 4>to cure cancer or address dementia, which are real social

0:04:32.640 --> 0:04:34.739
<v Speaker 4>problems and real issues that we want to pursue.

0:04:34.779 --> 0:04:37.000
<v Speaker 3>But no, we are not going to be in the

0:04:37.050 --> 0:04:37.950
<v Speaker 3>GLP-1 area.

0:04:38.029 --> 0:04:41.029
<v Speaker 2>How many employees does Johnson &amp; Johnson have?

0:04:41.050 --> 0:04:42.970
<v Speaker 3>We have 140,000 employees globally.

0:04:42.990 --> 0:04:43.969
<v Speaker 2>How many in the United States?

0:04:44.330 --> 0:04:47.590
<v Speaker 3>We have about 60,000 in the U.S., 80,000 globally.

0:04:48.350 --> 0:04:51.010
<v Speaker 2>And what are the revenues of Johnson &amp; Johnson now?

0:04:51.290 --> 0:04:54.610
<v Speaker 4>Our guidance this year is going to be somewhere north

0:04:54.650 --> 0:04:55.010
<v Speaker 4>of $ 100 billion.

0:04:56.460 --> 0:04:58.730
<v Speaker 2>Now, some people say that the United States is very

0:04:58.760 --> 0:05:01.550
<v Speaker 2>good at health care when you have a problem. We

0:05:01.589 --> 0:05:03.670
<v Speaker 2>have all kinds of drugs for things when you have

0:05:03.710 --> 0:05:06.450
<v Speaker 2>a problem. But what about prevention? We're not thought to

0:05:06.490 --> 0:05:10.190
<v Speaker 2>be as good in preventing health care problems as solving

0:05:10.230 --> 0:05:11.710
<v Speaker 2>them once you have them. What do you think about

0:05:11.740 --> 0:05:12.900
<v Speaker 2>that argument or criticism?

0:05:13.520 --> 0:05:15.320
<v Speaker 4>I think that we could do better as a country

0:05:15.360 --> 0:05:18.219
<v Speaker 4>in prevention. And I think that everything we can do

0:05:18.279 --> 0:05:21.420
<v Speaker 4>to improve our diet, our exercise, our lifestyle is going.

0:05:21.260 --> 0:05:21.700
<v Speaker 3>To be good.

0:05:21.800 --> 0:05:24.910
<v Speaker 4>And everything we can do to improve the primary care

0:05:25.010 --> 0:05:26.370
<v Speaker 4>side of healthcare in the U.S.

0:05:26.410 --> 0:05:27.789
<v Speaker 3>Will help in the prevention side.

0:05:27.870 --> 0:05:31.810
<v Speaker 4>Primary care is the first defense in healthcare and improving

0:05:31.850 --> 0:05:35.970
<v Speaker 4>primary care, it's an important element.

0:05:36.029 --> 0:05:38.740
<v Speaker 3>Now, I tell you, when it comes to specialized care,

0:05:38.839 --> 0:05:40.940
<v Speaker 3>clearly the U.S. is the lead in the world.

0:05:41.100 --> 0:05:44.420
<v Speaker 4>Everywhere I go, when somebody has a serious disease, they

0:05:44.460 --> 0:05:45.599
<v Speaker 4>think about coming to the U.S.

0:05:45.640 --> 0:05:47.380
<v Speaker 3>Because we have the best medicine in the world.

0:05:47.580 --> 0:05:49.740
<v Speaker 2>A number of years ago, the Affordable Care Act was

0:05:49.800 --> 0:05:53.260
<v Speaker 2>passed by Congress. and it was heavily criticized by some,

0:05:53.290 --> 0:05:55.850
<v Speaker 2>but supported by others. Do you think the Affordable Care

0:05:55.910 --> 0:05:59.229
<v Speaker 2>Act has been helpful to our US healthcare system? How

0:05:59.270 --> 0:06:01.100
<v Speaker 2>does it help you? And how would you change it

0:06:01.140 --> 0:06:01.839
<v Speaker 2>if you could change it?

0:06:02.420 --> 0:06:05.080
<v Speaker 4>My principle, our principle as a company is the more

0:06:05.100 --> 0:06:08.250
<v Speaker 4>people that has health coverage, the better for this country.

0:06:08.790 --> 0:06:11.870
<v Speaker 4>So anything that improves health coverage and more people covered,

0:06:12.290 --> 0:06:15.409
<v Speaker 4>the better for this country. It's important for a country

0:06:15.589 --> 0:06:19.169
<v Speaker 4>as rich as the US that we have health care

0:06:19.510 --> 0:06:20.330
<v Speaker 4>extended to as.

0:06:20.310 --> 0:06:22.310
<v Speaker 3>Many people as possible. So in that regard, I think

0:06:22.350 --> 0:06:22.710
<v Speaker 3>that's good.

0:06:22.830 --> 0:06:25.450
<v Speaker 4>And that's going to help in the areas of prevention

0:06:25.500 --> 0:06:26.360
<v Speaker 4>that you were mentioning.

0:06:26.690 --> 0:06:29.360
<v Speaker 3>That's going to help in life expectancy. That's good for

0:06:29.400 --> 0:06:29.839
<v Speaker 3>the country.

0:06:29.900 --> 0:06:33.200
<v Speaker 2>People say that sometimes the drugs in Canada or England

0:06:33.240 --> 0:06:35.229
<v Speaker 2>are cheaper. than they are in the United States for

0:06:35.250 --> 0:06:36.470
<v Speaker 2>the same drug. Have you ever heard of that?

0:06:36.810 --> 0:06:37.150
<v Speaker 3>It's true.

0:06:37.410 --> 0:06:40.610
<v Speaker 4>We are working in order to have the right recognition there.

0:06:40.670 --> 0:06:43.810
<v Speaker 4>But keep in mind that we are working with countries

0:06:43.830 --> 0:06:45.630
<v Speaker 4>that have a national health care system that has a

0:06:45.670 --> 0:06:50.790
<v Speaker 4>monopoly on that. And we have to obey for some

0:06:50.830 --> 0:06:53.560
<v Speaker 4>of these regulations unless we don't want these patients to

0:06:53.570 --> 0:06:54.300
<v Speaker 4>have that medicine.

0:06:54.600 --> 0:06:56.120
<v Speaker 2>It may not be a surprise to you, but a

0:06:56.180 --> 0:06:59.260
<v Speaker 2>lot of people in this country don't think that pharmaceutical

0:06:59.300 --> 0:07:02.380
<v Speaker 2>companies are very good. They charge high prices and things

0:07:02.420 --> 0:07:04.359
<v Speaker 2>like that. You're aware of this concern?

0:07:04.480 --> 0:07:05.620
<v Speaker 3>I'm aware, yeah.

0:07:05.760 --> 0:07:08.170
<v Speaker 2>So what are you trying to do in the pharmaceutical

0:07:08.230 --> 0:07:10.090
<v Speaker 2>industry to make people like you more?

0:07:10.670 --> 0:07:14.110
<v Speaker 4>Every time I talk to a patient that is using

0:07:14.190 --> 0:07:17.130
<v Speaker 4>one of our medicines and has a serious condition, they

0:07:17.170 --> 0:07:20.330
<v Speaker 4>like Johnson &amp; Johnson. And they like the pharmaceutical industry.

0:07:20.510 --> 0:07:22.470
<v Speaker 4>And they are grateful. And we do that a lot.

0:07:22.970 --> 0:07:25.210
<v Speaker 4>I mean, we bring a lot of patients to our offices.

0:07:25.290 --> 0:07:28.570
<v Speaker 4>We bring patients to our manufacturing sites. So our people

0:07:28.630 --> 0:07:31.060
<v Speaker 4>working in the company can connect what they do every

0:07:31.080 --> 0:07:33.900
<v Speaker 4>day with the impact those medicines have on patients or

0:07:33.940 --> 0:07:37.940
<v Speaker 4>those medical devices. So yes, we have a reputation depending,

0:07:38.440 --> 0:07:41.200
<v Speaker 4>but where we have a good reputation is in the

0:07:41.260 --> 0:07:43.720
<v Speaker 4>patients that use our medicines and medical technology.

0:07:43.800 --> 0:07:48.720
<v Speaker 2>Now, when you had a litigation issue years ago where

0:07:48.760 --> 0:07:51.690
<v Speaker 2>I think some kind of baby talc was said to

0:07:51.710 --> 0:07:55.750
<v Speaker 2>be carcinogenic. Maybe it was, I don't know. But then

0:07:55.770 --> 0:07:58.270
<v Speaker 2>when you spun it off, your consumer division, you still

0:07:58.330 --> 0:08:01.540
<v Speaker 2>kept the talc litigation. What's the status of that litigation?

0:08:01.980 --> 0:08:06.600
<v Speaker 4>So let me say first, you know, studies, regulatory agencies

0:08:06.620 --> 0:08:10.680
<v Speaker 4>have never found a causal relationship between talc and cancer.

0:08:11.120 --> 0:08:14.180
<v Speaker 4>So we stand behind that, and that's why we defend

0:08:14.240 --> 0:08:18.310
<v Speaker 4>our position there, and we litigate every single case that

0:08:18.490 --> 0:08:22.590
<v Speaker 4>comes with talk. There's a combination of third-party litigation funders

0:08:22.690 --> 0:08:25.280
<v Speaker 4>that invest in litigation, like if you were working in

0:08:25.460 --> 0:08:29.260
<v Speaker 4>infrastructure or if you were investing in technology, and they

0:08:29.380 --> 0:08:34.760
<v Speaker 4>fund these litigations, building pseudo-scientific arguments and try to play

0:08:34.880 --> 0:08:37.990
<v Speaker 4>in companies like us. That's the business model that exists here.

0:08:38.330 --> 0:08:41.870
<v Speaker 4>So we are litigating every single case. We are winning,

0:08:42.429 --> 0:08:44.730
<v Speaker 4>and at the same time, we are also trying to

0:08:44.870 --> 0:08:48.930
<v Speaker 4>introduce modifications in civil justice in order to make the

0:08:48.960 --> 0:08:49.920
<v Speaker 4>system more fair.

0:08:50.100 --> 0:08:52.860
<v Speaker 2>You must do consumer surveys. What is the most popular

0:08:53.240 --> 0:08:55.000
<v Speaker 2>thing that people tell you about what they like about

0:08:55.040 --> 0:08:56.220
<v Speaker 2>your company, what they don't like?

0:08:56.820 --> 0:08:59.720
<v Speaker 4>What they like about our company is normally the trust

0:08:59.780 --> 0:09:03.579
<v Speaker 4>that our medicines and medical technologies have on them. So

0:09:03.640 --> 0:09:05.569
<v Speaker 4>when they think Johnson &amp; Johnson, they think it's a

0:09:05.590 --> 0:09:08.350
<v Speaker 4>trust market. What they don't like about our company are the.

0:09:08.309 --> 0:09:09.350
<v Speaker 3>Prices, as usual.

0:09:09.450 --> 0:09:11.580
<v Speaker 2>What are you going to do about the prices?

0:09:11.980 --> 0:09:14.559
<v Speaker 4>Look, there's always going to be a tension between innovation

0:09:14.600 --> 0:09:19.160
<v Speaker 4>and affordability. Because innovation is expensive, it's high risk, and

0:09:19.260 --> 0:09:22.559
<v Speaker 4>we want to make that innovation gets to everybody in

0:09:22.600 --> 0:09:26.329
<v Speaker 4>this country. So we are always trying to price our

0:09:26.390 --> 0:09:28.550
<v Speaker 4>medicines in a way that is consistent with the benefit

0:09:28.570 --> 0:09:31.430
<v Speaker 4>they bring. In this country, we can work in different

0:09:31.590 --> 0:09:36.060
<v Speaker 4>areas in order to improve affordability. One area is trying

0:09:36.100 --> 0:09:39.950
<v Speaker 4>to take some of the percentage that the middlemen get

0:09:39.970 --> 0:09:45.090
<v Speaker 4>in pharmaceuticals, try to get back to the patient. We

0:09:45.110 --> 0:09:47.750
<v Speaker 4>can also, we should be doing that, we can also

0:09:47.809 --> 0:09:50.270
<v Speaker 4>have other countries that are developed countries paying the fair

0:09:50.330 --> 0:09:53.350
<v Speaker 4>share for recent development. All these things will help in

0:09:53.390 --> 0:09:55.150
<v Speaker 4>making medicines for Americans more affordable.

0:09:55.290 --> 0:09:57.880
<v Speaker 2>Let's talk about your story. You're born in Spain, What city?

0:09:58.280 --> 0:10:00.920
<v Speaker 4>I was born in Spain, in Valencia. I'm the son

0:10:00.980 --> 0:10:04.739
<v Speaker 4>of an engineer and a nurse. So I had the

0:10:04.860 --> 0:10:07.610
<v Speaker 4>medical side in my family and also the entrepreneurial side.

0:10:08.630 --> 0:10:10.950
<v Speaker 4>And I grew up in a large family. In my family,

0:10:10.990 --> 0:10:13.770
<v Speaker 4>my dad had nine brothers and sisters.

0:10:14.190 --> 0:10:16.729
<v Speaker 3>So I have like 40 cousins. And I was in

0:10:16.770 --> 0:10:17.209
<v Speaker 3>the middle.

0:10:17.770 --> 0:10:20.400
<v Speaker 4>So I realized at the beginning that I needed to

0:10:20.420 --> 0:10:22.680
<v Speaker 4>have a strong voice in order to be heard. Otherwise,

0:10:22.720 --> 0:10:25.020
<v Speaker 4>nobody was paying attention to me in my family.

0:10:25.059 --> 0:10:27.860
<v Speaker 2>Now, as I understand it, you went to college in

0:10:27.940 --> 0:10:28.660
<v Speaker 2>Spain initially.

0:10:28.679 --> 0:10:28.859
<v Speaker 3>Yeah.

0:10:29.500 --> 0:10:32.800
<v Speaker 2>And then after you graduated from college, you applied for

0:10:32.820 --> 0:10:35.330
<v Speaker 2>a job at Johnson &amp; Johnson and got turned down.

0:10:35.730 --> 0:10:36.850
<v Speaker 3>Yeah.

0:10:37.030 --> 0:10:39.310
<v Speaker 4>I got an interview and I didn't make it to

0:10:39.350 --> 0:10:40.370
<v Speaker 4>the second interview.

0:10:40.429 --> 0:10:42.790
<v Speaker 2>So what happened to the person who turned you down?

0:10:42.870 --> 0:10:43.530
<v Speaker 2>Is he still there?

0:10:43.929 --> 0:10:47.770
<v Speaker 4>He worked in the consumer business and look what happened

0:10:47.790 --> 0:10:48.970
<v Speaker 4>with consumer.

0:10:50.870 --> 0:10:51.210
<v Speaker 3>Okay.

0:10:51.350 --> 0:10:55.540
<v Speaker 2>All right. So now you worked your way up. Over

0:10:55.580 --> 0:10:57.580
<v Speaker 2>how many years have you been at Johnson &amp; Johnson?

0:10:57.600 --> 0:11:00.320
<v Speaker 3>I've been at Johnson &amp; Johnson. It goes fast. 37 years.

0:11:01.630 --> 0:11:03.300
<v Speaker 2>Did you ever think you could rise up to be

0:11:03.320 --> 0:11:03.840
<v Speaker 2>the CEO?

0:11:04.460 --> 0:11:06.660
<v Speaker 3>Never. I never thought I was going to be the CEO.

0:11:07.000 --> 0:11:09.720
<v Speaker 4>I tell you how I realized I could be the CEO,

0:11:09.740 --> 0:11:12.059
<v Speaker 4>because I was getting different jobs, and every time I

0:11:12.080 --> 0:11:13.560
<v Speaker 4>got that job, I thought, you know what, I can

0:11:13.600 --> 0:11:16.760
<v Speaker 4>do the next one. And then next job, I could

0:11:16.780 --> 0:11:18.420
<v Speaker 4>do the next one, I could do the next one,

0:11:18.600 --> 0:11:20.900
<v Speaker 4>until I became Vacher, and I said, I think I

0:11:20.920 --> 0:11:21.580
<v Speaker 4>can be CEO.

0:11:21.780 --> 0:11:24.080
<v Speaker 2>When did they tell you, like three years in advance?

0:11:24.280 --> 0:11:26.760
<v Speaker 4>They told me maybe a year and a half in advance.

0:11:26.980 --> 0:11:28.800
<v Speaker 4>They told me, you are going to be a candidate

0:11:28.820 --> 0:11:30.719
<v Speaker 4>to be CEO, and I have to go through a

0:11:30.780 --> 0:11:32.380
<v Speaker 4>process in order to become the CEO.

0:11:32.820 --> 0:11:34.330
<v Speaker 2>And did you tell them what was wrong with all

0:11:34.350 --> 0:11:35.949
<v Speaker 2>the other candidates, or you didn't tell them that?

0:11:36.150 --> 0:11:38.170
<v Speaker 3>They didn't tell me anything. They just told me, you're

0:11:38.190 --> 0:11:39.050
<v Speaker 3>going to be the next one.

0:11:39.170 --> 0:11:40.890
<v Speaker 2>Do you have children who want to be in the

0:11:40.929 --> 0:11:41.550
<v Speaker 2>healthcare world?

0:11:42.230 --> 0:11:45.260
<v Speaker 4>I have a daughter who is in medical school, and

0:11:45.280 --> 0:11:48.380
<v Speaker 4>I have a son who is a mechanical engineer. But yeah,

0:11:49.080 --> 0:11:50.730
<v Speaker 4>I have a tradition in my family, as I told you,

0:11:50.750 --> 0:11:54.500
<v Speaker 4>my My mom was a nurse. My grandmother was a pharmacist.

0:11:54.559 --> 0:11:57.459
<v Speaker 4>My grandfather, a pediatrician. And I spent a lot of

0:11:57.500 --> 0:12:01.420
<v Speaker 4>my childhood in Valencia, my hometown, in my grandmother's pharmacy.

0:12:01.450 --> 0:12:03.890
<v Speaker 4>She had a retail pharmacy. And when my mom was

0:12:03.950 --> 0:12:07.010
<v Speaker 4>doing errands in town, she would let me in the

0:12:07.050 --> 0:12:09.610
<v Speaker 4>pharmacy waiting with my grandmother because she was manning the

0:12:09.630 --> 0:12:12.450
<v Speaker 4>pharmacy herself. And she was talking to patients coming to

0:12:12.490 --> 0:12:15.480
<v Speaker 4>refill prescriptions all the time. And I would always complain, grandma,

0:12:15.520 --> 0:12:17.880
<v Speaker 4>why do you talk to people so much? where you

0:12:17.900 --> 0:12:20.620
<v Speaker 4>spend so much time with the people. And she told me,

0:12:20.640 --> 0:12:23.679
<v Speaker 4>I remember that, Joaquin, the important thing is not the medicine,

0:12:23.860 --> 0:12:27.140
<v Speaker 4>it's the person. So I always retain that to myself.

0:12:27.220 --> 0:12:30.990
<v Speaker 4>It's not the medicine, it's the person.

0:12:32.370 --> 0:12:34.770
<v Speaker 2>So if you're the healthcare CEO of the biggest healthcare

0:12:34.830 --> 0:12:37.220
<v Speaker 2>company in the world, you should be really fit. And

0:12:37.240 --> 0:12:39.860
<v Speaker 2>you seem like you're fit, but what do you do

0:12:39.900 --> 0:12:41.599
<v Speaker 2>to save? I mean, do you exercise every day? Do

0:12:41.620 --> 0:12:43.750
<v Speaker 2>you have an instructor to teach you how to make

0:12:43.760 --> 0:12:45.170
<v Speaker 2>sure you look fit and are fit?

0:12:45.510 --> 0:12:48.589
<v Speaker 4>So I exercise a couple of days a week, and

0:12:48.610 --> 0:12:50.809
<v Speaker 4>then I play tennis over the weekend. They say tennis

0:12:50.850 --> 0:12:52.740
<v Speaker 4>is the best sport in order to be fit.

0:12:53.550 --> 0:12:55.920
<v Speaker 3>Because you have to exercise your mind and your body.

0:12:56.260 --> 0:12:58.140
<v Speaker 4>And there are many studies that show that tennis is

0:12:58.160 --> 0:12:59.800
<v Speaker 4>the one that creates more longevity.

0:12:59.980 --> 0:13:01.400
<v Speaker 2>So that's why I'm testing it. So do you play

0:13:01.420 --> 0:13:03.200
<v Speaker 2>with Rafael Nadal? I wish.

0:13:03.220 --> 0:13:03.760
<v Speaker 3>I wish.

0:13:04.240 --> 0:13:07.290
<v Speaker 4>I play with a coach. And I plan that. I

0:13:07.309 --> 0:13:09.190
<v Speaker 4>play twice a week. And I really love it.

0:13:09.710 --> 0:13:11.450
<v Speaker 2>How much of your time do you spend on the road?

0:13:12.110 --> 0:13:13.570
<v Speaker 3>I would say 75%. 75%? Yeah.

0:13:13.830 --> 0:13:16.770
<v Speaker 2>So who's watching the store back in?

0:13:17.220 --> 0:13:21.140
<v Speaker 4>Look, I mean, I have a lot of people back

0:13:21.160 --> 0:13:23.000
<v Speaker 4>in the store, so that is watching for me.

0:13:23.640 --> 0:13:25.520
<v Speaker 3>And it's important for me to be connected.

0:13:25.920 --> 0:13:28.520
<v Speaker 4>I have to be connected to the physicians that use

0:13:28.580 --> 0:13:31.970
<v Speaker 4>our medicines and medical technologies. I have to be connected

0:13:32.030 --> 0:13:33.750
<v Speaker 4>with our employees here in the.

0:13:33.750 --> 0:13:36.210
<v Speaker 3>US and elsewhere. I have to have a pulse of

0:13:36.250 --> 0:13:38.510
<v Speaker 3>the company. I cannot have a pulse of the company

0:13:38.910 --> 0:13:40.390
<v Speaker 3>if I am at New Brunswick.

0:13:40.630 --> 0:13:44.809
<v Speaker 2>What is the hardest part about being CEO of Johnson &amp; Johnson?

0:13:44.850 --> 0:13:46.290
<v Speaker 2>What's the biggest challenge you face?

0:13:47.340 --> 0:13:49.460
<v Speaker 4>The biggest challenge is to be able to continue to

0:13:49.480 --> 0:13:52.580
<v Speaker 4>improve this company every day. I mean, these companies as

0:13:52.640 --> 0:13:54.900
<v Speaker 4>big as Johnson &amp; Johnson, we need to have attention

0:13:54.980 --> 0:13:59.560
<v Speaker 4>to improvement, to reinvent ourselves. So the biggest challenge for

0:13:59.620 --> 0:14:02.859
<v Speaker 4>a CEO is to break the inertia and to make

0:14:02.900 --> 0:14:04.770
<v Speaker 4>the company every day more competitive.

0:14:05.330 --> 0:14:06.830
<v Speaker 3>And that's what I'm trying every day.

0:14:07.620 --> 0:14:09.979
<v Speaker 2>If you were to educate somebody to this audience and

0:14:10.020 --> 0:14:12.300
<v Speaker 2>you say, here's something you should know about healthcare that

0:14:12.320 --> 0:14:14.120
<v Speaker 2>you really don't know or you should know more about,

0:14:14.160 --> 0:14:14.750
<v Speaker 2>what would that be?

0:14:15.370 --> 0:14:17.190
<v Speaker 4>Yeah, so I would say first, in becoming CEO of

0:14:17.230 --> 0:14:19.770
<v Speaker 4>Johnson &amp; Johnson, I think this is a sign of

0:14:19.810 --> 0:14:22.960
<v Speaker 4>the opportunities that exist in this country. I think the U.S.

0:14:22.990 --> 0:14:26.260
<v Speaker 4>is a great country. It's a land of opportunity and Look,

0:14:26.320 --> 0:14:28.280
<v Speaker 4>I was born in Spain, but I am more an

0:14:28.300 --> 0:14:31.480
<v Speaker 4>American from a professional perspective. I love the sense of

0:14:31.520 --> 0:14:34.900
<v Speaker 4>opportunity of this country. I love the opportunity to progress

0:14:34.970 --> 0:14:37.489
<v Speaker 4>and make your dreams come true, like me becoming CEO

0:14:37.530 --> 0:14:38.330
<v Speaker 4>of Johnson &amp; Johnson.

0:14:38.370 --> 0:14:40.330
<v Speaker 3>So as a U.S.

0:14:40.390 --> 0:14:42.430
<v Speaker 4>Citizen that was not born in the U.S., I have

0:14:42.470 --> 0:14:44.990
<v Speaker 4>to say this is a wonderful country. And sometimes you

0:14:45.030 --> 0:14:47.770
<v Speaker 4>have to be from outside to appreciate what a great

0:14:47.820 --> 0:14:50.220
<v Speaker 4>country this is. So I'm very grateful for this country

0:14:50.300 --> 0:14:53.070
<v Speaker 4>and the opportunities they gave me. So as far as

0:14:53.550 --> 0:14:55.810
<v Speaker 4>what I would say in healthcare, I would say trust

0:14:55.830 --> 0:14:59.620
<v Speaker 4>your doctor. I think doctors and nurses and healthcare workers

0:14:59.740 --> 0:15:02.200
<v Speaker 4>are really the frontline of our health, and I think

0:15:02.240 --> 0:15:05.480
<v Speaker 4>that trusting your doctor, your nurse, is a very important

0:15:05.520 --> 0:15:08.480
<v Speaker 4>thing for us. That's why, as Johnson &amp; Johnson, our

0:15:08.580 --> 0:15:11.760
<v Speaker 4>focus in terms of our philanthropic activities is in frontline

0:15:11.800 --> 0:15:15.100
<v Speaker 4>healthcare workers, is in nurses. We think that's the frontline

0:15:15.160 --> 0:15:17.280
<v Speaker 4>of healthcare, and my advice is trust them.

0:15:18.440 --> 0:15:21.790
<v Speaker 2>Now, in the United States, there are only two companies

0:15:22.670 --> 0:15:25.470
<v Speaker 2>that have a triple A credit rating. Does anybody else

0:15:25.750 --> 0:15:27.770
<v Speaker 2>know what, one is Johnson &amp; Johnson, anybody else know

0:15:27.790 --> 0:15:29.570
<v Speaker 2>what the other one is? That is the only other

0:15:29.610 --> 0:15:31.710
<v Speaker 2>company in the United States, publicly traded company, that has

0:15:31.750 --> 0:15:37.960
<v Speaker 2>a triple A credit rating. Anybody? What? Microsoft is the company.

0:15:38.060 --> 0:15:41.710
<v Speaker 3>Microsoft, yeah, Microsoft and Johnson &amp; Johnson. We're proud. to

0:15:41.750 --> 0:15:43.210
<v Speaker 3>have a AAA credit rating.

0:15:43.230 --> 0:15:50.540
<v Speaker 4>I think it's a better credit rating than the US government.

0:15:50.860 --> 0:15:54.180
<v Speaker 4>It's a sign of our financial discipline and our trajectory

0:15:54.200 --> 0:15:57.860
<v Speaker 4>over a long period of time. And many investors ask me,

0:15:58.120 --> 0:16:01.280
<v Speaker 4>why having a AAA credit rating? You could be more leveraged.

0:16:02.260 --> 0:16:04.500
<v Speaker 4>I say, look, it's a sign of our financial discipline.

0:16:04.620 --> 0:16:07.770
<v Speaker 4>We are not married to the AAA credit rating. If

0:16:08.010 --> 0:16:09.930
<v Speaker 4>a good opportunity would come along, we would be happy

0:16:09.970 --> 0:16:12.070
<v Speaker 4>not to have a... a triple-A credit rating, but it's

0:16:12.110 --> 0:16:14.860
<v Speaker 4>a sign of our financial discipline, and our investors like it.

0:16:15.410 --> 0:16:18.910
<v Speaker 2>For 15 years in a row, you've had an annual

0:16:19.550 --> 0:16:21.550
<v Speaker 2>dividend that has increased, is that right?

0:16:21.970 --> 0:16:22.990
<v Speaker 3>More than 50 years.

0:16:23.150 --> 0:16:23.730
<v Speaker 2>More than 50 years.

0:16:23.750 --> 0:16:25.750
<v Speaker 3>More than 50 years we have increased our dividend, yeah, yeah.

0:16:26.130 --> 0:16:28.210
<v Speaker 2>So that's pretty good. Do you try very hard to

0:16:28.230 --> 0:16:29.390
<v Speaker 2>make sure you do that every year?

0:16:29.670 --> 0:16:32.670
<v Speaker 4>That's sacrosanct. You know, when investors ask me, what about

0:16:32.700 --> 0:16:34.840
<v Speaker 4>the dividend? I say, that's always going to be there,

0:16:34.880 --> 0:16:37.680
<v Speaker 4>that you can bet that you will have a dividend

0:16:37.720 --> 0:16:39.820
<v Speaker 4>growth if you are investing in Johnson &amp; Johnson.

0:16:40.180 --> 0:16:42.880
<v Speaker 2>The most commonly asked question of CEOs today is how

0:16:42.940 --> 0:16:45.800
<v Speaker 2>is your company being affected by AI and what are

0:16:45.820 --> 0:16:48.060
<v Speaker 2>you doing to take advantage of AI? So how are

0:16:48.080 --> 0:16:50.040
<v Speaker 2>you being affected by AI and how are you taking

0:16:50.120 --> 0:16:50.780
<v Speaker 2>advantage of AI?

0:16:51.040 --> 0:16:53.380
<v Speaker 4>On the positive, you know, AI for us is a

0:16:53.420 --> 0:16:56.800
<v Speaker 4>force multiplier because AI, it's going to help life science

0:16:56.860 --> 0:16:59.080
<v Speaker 4>companies like Johnson &amp; Johnson to be able to develop

0:16:59.100 --> 0:17:02.250
<v Speaker 4>better medicines and medical technology. So we have to embrace AI.

0:17:03.090 --> 0:17:06.390
<v Speaker 4>AI is going to accelerate discovery of new medicines. AI

0:17:06.410 --> 0:17:09.649
<v Speaker 4>is going to make medical devices smarter, be able to

0:17:09.710 --> 0:17:12.859
<v Speaker 4>navigate the body better. So I think AI is something

0:17:12.880 --> 0:17:15.160
<v Speaker 4>that a company like Johnson &amp; Johnson has to embrace. Now,

0:17:15.220 --> 0:17:19.060
<v Speaker 4>we have to help all our employees to amplify what

0:17:19.100 --> 0:17:21.820
<v Speaker 4>they do with AI. And we are training all our

0:17:21.859 --> 0:17:24.699
<v Speaker 4>employees in AI because we want to bring everybody in

0:17:24.740 --> 0:17:27.330
<v Speaker 4>the journey. AI is not going to take your job,

0:17:27.369 --> 0:17:29.770
<v Speaker 4>but somebody with AI skills may take your job.

0:17:30.070 --> 0:17:31.810
<v Speaker 2>Are you spending a lot of money now on AI?

0:17:32.450 --> 0:17:34.649
<v Speaker 4>We are investing in AI, too, in programs that are

0:17:34.690 --> 0:17:38.400
<v Speaker 4>going to improve the operations of the company in areas

0:17:38.480 --> 0:17:41.500
<v Speaker 4>like drug discovery, where I think AI is going to

0:17:41.520 --> 0:17:45.300
<v Speaker 4>have a big impact, in areas like making our medical

0:17:45.340 --> 0:17:47.320
<v Speaker 4>devices smarter, our robotic systems.

0:17:47.340 --> 0:17:49.370
<v Speaker 3>So we are investing in AI.

0:17:49.570 --> 0:17:52.490
<v Speaker 2>Like in my age, I'm focused on drugs that are

0:17:53.070 --> 0:17:55.469
<v Speaker 2>Alzheimer's related. Is that something you're focused on?

0:17:55.930 --> 0:17:56.170
<v Speaker 3>Yeah.

0:17:56.710 --> 0:17:57.760
<v Speaker 2>Because that's going to be a big....

0:17:59.070 --> 0:18:02.730
<v Speaker 4>I think the biggest challenge for the healthcare industry and

0:18:02.810 --> 0:18:05.919
<v Speaker 4>for the pharmaceutical and medical device industry is to address

0:18:05.960 --> 0:18:09.300
<v Speaker 4>the issue of neurodegeneration and dementia.

0:18:09.320 --> 0:18:10.520
<v Speaker 3>I mean, it's a real.

0:18:10.340 --> 0:18:14.179
<v Speaker 4>Social problem that your chances of having some type of

0:18:14.240 --> 0:18:15.620
<v Speaker 4>cognitive impairment.

0:18:15.619 --> 0:18:16.700
<v Speaker 3>Increase as you age.

0:18:17.100 --> 0:18:20.440
<v Speaker 4>And as we are increasing our age, the likelihood of

0:18:20.500 --> 0:18:22.860
<v Speaker 4>having more people with dementia is higher. So I think

0:18:22.900 --> 0:18:26.840
<v Speaker 4>this is the most important problem, in my view, that

0:18:26.859 --> 0:18:28.939
<v Speaker 4>the industry can address. And we are working on that,

0:18:29.030 --> 0:18:31.270
<v Speaker 4>as Johnson &amp; Johnson, in trying to identify that.

0:18:31.330 --> 0:18:33.590
<v Speaker 3>We're trying, we fail, and we come back again.

0:18:34.290 --> 0:18:35.370
<v Speaker 2>What about cancer?

0:18:36.230 --> 0:18:39.480
<v Speaker 4>Cancer, we aim to be the number one company in cancer.

0:18:40.440 --> 0:18:43.840
<v Speaker 4>Our goal is to be number one by 2030. Perhaps

0:18:43.920 --> 0:18:46.909
<v Speaker 4>it's the best sign of where the company is heading.

0:18:46.970 --> 0:18:49.550
<v Speaker 4>What is the new Johnson &amp; Johnson about is trying

0:18:49.590 --> 0:18:52.840
<v Speaker 4>to eliminate cancer. The basic areas that we're working, I

0:18:52.900 --> 0:18:57.180
<v Speaker 4>mentioned multiple myeloma, we're also working in lung cancer, bladder cancer,

0:18:57.460 --> 0:19:01.149
<v Speaker 4>prostate cancer, colorectal cancer, head and neck cancer. So we

0:19:01.170 --> 0:19:05.030
<v Speaker 4>have multiple medicines to address a number of cancers that

0:19:05.530 --> 0:19:08.950
<v Speaker 4>have common oncogenic drivers. Cancer is an area in which

0:19:09.250 --> 0:19:12.890
<v Speaker 4>progress is occurring at an accelerated pace. On one hand,

0:19:13.230 --> 0:19:15.909
<v Speaker 4>we understand better the biology of the disease, and on

0:19:15.930 --> 0:19:19.130
<v Speaker 4>the other hand, we have better technologies to kill cancer cells.

0:19:20.210 --> 0:19:22.350
<v Speaker 2>So when you want to get a new product, let's

0:19:22.369 --> 0:19:26.610
<v Speaker 2>say in Alzheimer's or cancer, you can develop it yourself

0:19:26.710 --> 0:19:29.290
<v Speaker 2>in terms of your own lab, and that might take

0:19:29.290 --> 0:19:31.679
<v Speaker 2>15 years or so, or you can go buy it

0:19:31.740 --> 0:19:35.080
<v Speaker 2>from somebody else. What percentage of your products that you

0:19:35.119 --> 0:19:40.000
<v Speaker 2>now sell in pharmaceutical and in medical devices did you

0:19:40.060 --> 0:19:43.160
<v Speaker 2>actually develop yourself, and what percentage did you actually buy

0:19:43.200 --> 0:19:43.770
<v Speaker 2>from somebody else?

0:19:44.180 --> 0:19:47.910
<v Speaker 4>So we always aim to have a happy mix of 50-50,

0:19:48.410 --> 0:19:52.710
<v Speaker 4>internal and external, Uh, It's not realistic for a company

0:19:52.730 --> 0:19:55.149
<v Speaker 4>to think that all the best things are going to

0:19:55.260 --> 0:19:58.100
<v Speaker 4>occur in your labs. You have to be aware that

0:19:58.150 --> 0:20:00.199
<v Speaker 4>some of the best science is not going to be

0:20:00.260 --> 0:20:02.500
<v Speaker 4>occurring in the walls of Johnson &amp; Johnson. So we

0:20:02.540 --> 0:20:08.480
<v Speaker 4>have a very sophisticated system of scientific scouts identifying external innovation.

0:20:08.940 --> 0:20:11.240
<v Speaker 4>Most of the times, we identify things that are quite

0:20:11.400 --> 0:20:14.619
<v Speaker 4>early on that will still take many years to get

0:20:14.660 --> 0:20:17.100
<v Speaker 4>into the market. For example, we just bought a company

0:20:17.460 --> 0:20:20.810
<v Speaker 4>that has a system to kill cancer cells. I think

0:20:20.850 --> 0:20:24.470
<v Speaker 4>the first medicine coming from that company may come mid-30s.

0:20:24.869 --> 0:20:26.530
<v Speaker 3>So is that internal or external?

0:20:26.850 --> 0:20:29.389
<v Speaker 4>Because for us to get that medicine into the market,

0:20:29.410 --> 0:20:32.830
<v Speaker 4>we have to do some adjustments in the chemical structure.

0:20:32.869 --> 0:20:35.709
<v Speaker 4>We have to be able to develop and do all

0:20:35.760 --> 0:20:38.960
<v Speaker 4>the clinical development and develop all the manufacturing process and

0:20:39.000 --> 0:20:41.960
<v Speaker 4>bring it to market. So we have a happy 50-50

0:20:42.100 --> 0:20:45.560
<v Speaker 4>external and internal innovation for a company that is focused

0:20:45.700 --> 0:20:49.430
<v Speaker 4>on medical breakthroughs. Having a good system of external innovation

0:20:49.510 --> 0:20:50.310
<v Speaker 4>is fundamental.

0:20:50.950 --> 0:20:54.369
<v Speaker 2>Now, some people say that in China, they take American

0:20:54.750 --> 0:20:58.040
<v Speaker 2>healthcare products that are patented and then they kind of

0:20:58.300 --> 0:21:01.060
<v Speaker 2>copy them, counterfeit them, and sell them. Is there any

0:21:01.140 --> 0:21:01.680
<v Speaker 2>evidence of that?

0:21:02.240 --> 0:21:05.969
<v Speaker 4>China is making a lot of strides in healthcare and

0:21:06.130 --> 0:21:08.890
<v Speaker 4>everything is incremental. At the beginning, you start copying, but

0:21:09.190 --> 0:21:12.250
<v Speaker 4>gradually you start improving and you start discovering new things

0:21:12.270 --> 0:21:15.830
<v Speaker 4>yourself too. So I think clearly we have competition from

0:21:15.910 --> 0:21:19.070
<v Speaker 4>China when it comes to innovation. I don't think China

0:21:19.190 --> 0:21:21.930
<v Speaker 4>is at the level of breakthrough innovation that the U.S.

0:21:21.970 --> 0:21:22.070
<v Speaker 3>Is.

0:21:22.109 --> 0:21:26.240
<v Speaker 4>China didn't discovered the GLP-1s or didn't discover the CAR

0:21:26.300 --> 0:21:29.500
<v Speaker 4>T cell therapy or the immunotherapy in cancer, but they

0:21:29.520 --> 0:21:32.889
<v Speaker 4>are good in being fast followers and that only has

0:21:32.910 --> 0:21:36.359
<v Speaker 4>to stimulate the US that has the best ecosystem in

0:21:36.410 --> 0:21:38.189
<v Speaker 4>order to be able to invest more in healthcare. We

0:21:38.210 --> 0:21:40.419
<v Speaker 4>have to invest more in research, we have to continue

0:21:40.440 --> 0:21:43.060
<v Speaker 4>to protect the intellectual property, we have to attract the

0:21:43.100 --> 0:21:45.480
<v Speaker 4>best talent, we have to have a good market, and

0:21:45.540 --> 0:21:48.100
<v Speaker 4>if we do that, we're gonna continue being the number

0:21:48.200 --> 0:21:51.440
<v Speaker 4>one country in life science innovation, which is good economically,

0:21:51.740 --> 0:21:53.160
<v Speaker 4>and it's also good for the patients here.

0:21:53.520 --> 0:21:55.820
<v Speaker 2>If I wanted to buy a stock in a healthcare company,

0:21:56.240 --> 0:21:58.320
<v Speaker 2>would Johnson &amp; Johnson be a good stock to buy?

0:21:59.590 --> 0:22:01.790
<v Speaker 3>David, you're a smart man. It would be the best

0:22:01.990 --> 0:22:04.750
<v Speaker 3>stock to buy, Johnson &amp; Johnson. No question. I'm going

0:22:04.770 --> 0:22:07.119
<v Speaker 3>to give you some reasons why. We are just at

0:22:07.180 --> 0:22:07.860
<v Speaker 3>the beginning.

0:22:08.119 --> 0:22:10.800
<v Speaker 4>This is just the initial innings of a cycle of

0:22:10.840 --> 0:22:13.980
<v Speaker 4>growth for Johnson &amp; Johnson. We were saying that we

0:22:14.020 --> 0:22:16.600
<v Speaker 4>have line of sight to double-digit growth by the end

0:22:16.640 --> 0:22:19.820
<v Speaker 4>of the decade, and that's remarkable. for a company which

0:22:19.920 --> 0:22:22.520
<v Speaker 4>is more than $ 100 billion. And you know why? We

0:22:22.580 --> 0:22:25.500
<v Speaker 4>are not a one-trick pony company. We have a whole

0:22:25.560 --> 0:22:29.500
<v Speaker 4>stable of medicines and medical devices. We have 28 platforms

0:22:29.940 --> 0:22:32.280
<v Speaker 4>of more than a billion dollars. So we don't depend

0:22:32.380 --> 0:22:35.720
<v Speaker 4>on a single platform. And that creates much more optionality

0:22:35.770 --> 0:22:38.270
<v Speaker 4>to be able to bring breakthroughs and at the same

0:22:38.290 --> 0:22:39.409
<v Speaker 4>time to create more revenue.

0:22:39.670 --> 0:22:41.449
<v Speaker 2>Since you've been in the healthcare world, what do you

0:22:41.470 --> 0:22:45.510
<v Speaker 2>think is the single greatest healthcare invention or creation? It's

0:22:45.910 --> 0:22:48.419
<v Speaker 2>this discovery of certain kind of drugs. What do you

0:22:48.440 --> 0:22:51.160
<v Speaker 2>think has changed the world of healthcare more than anything

0:22:51.200 --> 0:22:52.980
<v Speaker 2>else in the years that you've been in the healthcare world?

0:22:53.470 --> 0:22:55.230
<v Speaker 3>I mean, I have seen a lot of progress.

0:22:55.430 --> 0:22:58.389
<v Speaker 4>I mean, I've seen how life expectancy increase in the

0:22:58.410 --> 0:23:01.380
<v Speaker 4>20th century more than 30 years. I have seen how

0:23:01.700 --> 0:23:05.700
<v Speaker 4>HIV got to be a curable disease. I have seen

0:23:05.760 --> 0:23:10.340
<v Speaker 4>how we develop vaccines that have been extremely positive preventive tools.

0:23:10.880 --> 0:23:14.899
<v Speaker 4>I have seen how we have improved cardiovascular mortality and

0:23:14.940 --> 0:23:19.440
<v Speaker 4>morbidity through multiple prevention in hypertension, in statins. So I

0:23:19.500 --> 0:23:22.630
<v Speaker 4>have seen many, many positive things. Perhaps the most positive

0:23:22.650 --> 0:23:25.190
<v Speaker 4>things that I'm seeing now is how we are improving

0:23:25.250 --> 0:23:26.470
<v Speaker 4>our treatment of cancer.

0:23:27.109 --> 0:23:28.730
<v Speaker 3>The cancer death rates are coming down.

0:23:29.330 --> 0:23:32.120
<v Speaker 4>We are much better as a country than any other

0:23:32.170 --> 0:23:34.359
<v Speaker 4>country in the world, and we have the ambition to

0:23:34.420 --> 0:23:35.240
<v Speaker 4>eliminate cancer.

0:23:36.900 --> 0:23:39.400
<v Speaker 2>Thanks for listening. To hear more of my interviews, you

0:23:39.440 --> 0:23:43.590
<v Speaker 2>can subscribe and download my podcast on Spotify, Apple, or

0:23:43.619 --> 0:23:44.350
<v Speaker 2>wherever you listen.